Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.” ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., ...

The 2026 ARCA Menards Series season gets started on Saturday afternoon at Daytona International Speedway. Tune in to FOX to watch the Daytona ARCA 200. Last season, Brenden Queen, who is now running ...

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.

PASADENA, Calif., Feb. 9, 2026 /PRNewswire/ -- Bidding opens on February 11 in a major Tiger Group biopharma-industry auction of new and late-model GMP Manufacturing and Quality Control Laboratory ...

Dealmaking continued to be a key part of company strategies to address challenges facing the biopharma industry in 2025, including drug pricing pressures, a difficult biotech funding market and the ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. Now with its innovative drug franchise ...

Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. A tough biotech investing environment, aggressive direct-to-consumer drug marketing ...

UBS global head of Biotechnology Research Michael Yee is bullish on biopharma stocks for the year ahead, declaring the sector is “ready to take off” after enduring a difficult three-to-four-year ...

An update from Aspire Biopharma Holdings ( (ASBP)) is now available. On January 1, 2026, Aspire Biopharma Holdings entered into exchange agreements with certain former PowerUp Acquisition Corp.